# Vactosertib and Durvalumab in Gastric Cancer

> **NCT04893252** · PHASE2 · UNKNOWN · sponsor: **Hark Kyun Kim** · enrollment: 55 (estimated)

## Conditions studied

- Stomach Neoplasm

## Interventions

- **DRUG:** durvalumab and vactosertib

## Key facts

- **NCT ID:** NCT04893252
- **Lead sponsor:** Hark Kyun Kim
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893252, "Vactosertib and Durvalumab in Gastric Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04893252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*